Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691056 | 0.87 | GAA (0.55) | ALDH1A1GAAPKMTDP1TSHR | |
| SCHEMBL7437807 | 0.83 | HSP90AB1 (0.49) | HSP90AB1HTTALDH1A1GAAGFER | |
| SCHEMBL14626659 | 0.80 | HSP90AB1 (0.40) | HSP90AB1HTTALDH1A1THRB | |
| SCHEMBL2432860 | 0.78 | ALDH1A1 (0.54) | HTTALDH1A1PKMKDM4EPOLB | |
| SCHEMBL5690976 | 0.77 | GAA (0.53) | HTTALDH1A1GAAPKMTDP1 | |
| SCHEMBL3456779 | 0.76 | HSP90AB1 (0.63) | HSP90AB1ALDH1A1GAAGFERPKM | |
| SCHEMBL5690995 | 0.76 | HSP90AB1 (0.54) | HSP90AB1HTTALDH1A1GAAGFER | |
| SCHEMBL2593349 | 0.75 | CYP1A2 (0.50) | ALDH1A1GAAGFERTDP1TSHR | |
| SCHEMBL68918 | 0.75 | MAPT (0.45) | HTTALDH1A1GAAPKMTDP1 | |
| SCHEMBL26831175 | 0.75 | XDH (0.51) | HTTALDH1A1GAAGFERPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153017-B1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | AVENTIS PHARMA LTD (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-6593354-B2 | Amide substituted benzimidazole or benzoxazole; regulating the interaction of vascular cell adhesion molecule-1 and fibronectin with the integrin vascular cell adhesion molecule very late antigen-4 | AVENTIS PHARMA LIMITED (GB) | 2003-07-15 | — | — | US | disclosed |
| US-20020137782-A1 | Substituted bicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2002-09-26 | — | — | US | disclosed |
| EP-1153017-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | Aventis Pharma Limited (GB) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049005-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS | AVENTIS PHARMA LIMITED (GB) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137782-A1 | Substituted bicyclic compounds | ITGA1, VCAM1, ITGB1 | HSP90AB1 3328/4885HTT 4777/4885ALDH1A1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.